Targeting the proper amyloid-beta neuronal toxins: A path forward for Alzheimer's disease immunotherapeutics

Alzheimer's Research and Therapy

Volumn 6, Issue 4, 2014, Pages

  Goure, William F ^a   Krafft, Grant A ^a   Jerecic, Jasna ^a   Hefti, Franz ^a  

^a Acumen Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; AMYLIN RECEPTOR; AMYLOID BETA PROTEIN; BAN 2401; BAPINEUZUMAB; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; CALCINEURIN; COFILIN; CRENEZUMAB; CYCLIN DEPENDENT KINASE 5; DYNAMIN; GANTENERUMAB; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR; MONOMER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; PONEZUMAB; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SAR 228810; SIGMA 2 OPIATE RECEPTOR; SOLANEZUMAB; SORTILIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; CEREBROSPINAL FLUID LEVEL; DEGENERATIVE DISEASE; HUMAN; IMMUNOTHERAPY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

EID: 84904204899     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt272     Document Type: Review

References (224)

1. Alzheimer's Disease International, World Alzheimer Report, 2010: The Global Economic Impact of Dementia. Alzheimer's Disease International 2010 [ http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf ] 24946077
2. - 2013 Alzheimer's disease facts and figures. TW Bleiler, Alzheimers Dement 2013 9 208 245 [ http://www.alz.org/downloads/facts-figures-2013.pdf ] 23507120
3. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. DJ Selkoe, J Alzheimers Dis 2001 3 75 80 12214075
4. Aβ oligomers-a decade of discovery. DM Walsh, DJ Selkoe, J Neurochem 2007 101 1172 1184 10.1111/j.1471-4159.2006.04426.x 17286590 (Pubitemid 46718812)
5. Amyloid β-protein assembly and Alzheimer disease. R Roychaudhuri, M Yang, MM Hoshi, DB Teplow, J Biol Chem 2009 284 4749 4753 10.1074/jbc.R800036200 18845536
6. Alzheimer's disease amyloid β-protein and synaptic function. T Ondrejcak, I Klyubin, N-W Hu, AE Barry, WK Cullen, MJ Rowan, Neuromol Med 2010 12 13 26 10.1007/s12017-009-8091-0
7. Amyloid oligomers: formation and toxicity of Aβ oligomers. M Sakono, T Zako, FEBS J 2010 277 1348 1358 10.1111/j.1742-4658.2010.07568.x 20148964
8. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. ST Ferreira, WL Klein, Neurobiol Learn Mem 2011 96 529 543 10.1016/j.nlm.2011.08.003 21914486
9. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. I Benilova, E Karran, B De Strooper, Nat Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
10. Amyloid β-protein oligomers and Alzheimer's disease. EY Hayden, DB Teplow, Alzheimers Res Ther 2013 5 60 10.1186/alzrt226 24289820
11. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. CW Wong, V Quaranta, GG Glenner, Proc Natl Acad Sci USA 1985 82 8729 8732 10.1073/pnas.82.24.8729 2934737 (Pubitemid 16101117)
12. Alzheimer's disease: the amyloid cascade hypothesis. JA Hardy, GA Higgins, Science 1992 256 184 185 10.1126/science.1566067 1566067
13. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? WL Klein, GA Krafft, CE Finch, Trends Neurosci 2001 24 219 224 10.1016/S0166-2236(00)01749-5 11250006 (Pubitemid 32204378)
14. β-Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. FG De Felice, ST Ferreira, Cell Mol Neurobiol 2002 22 545 563 10.1023/A:1021832302524 12585679 (Pubitemid 36169208)
15. Strategies for disease modification in Alzheimer's disease. M Citron, Nat Rev Neurosci 2004 5 677 685 10.1038/nrn1495 15322526 (Pubitemid 39150139)
16. Initiation and propagation of neurodegeneration. C Haas, Nat Med 2010 16 1201 1204 10.1038/nm.2223 21052073
17. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation. K Broersen, F Rousseau, J Schymkowitz, Alzheimers Res Ther 2010 2 12 10.1186/alzrt36 20642866
18. Aβ oligomer-induced synapse degeneration in Alzheimer's disease. KC Wilcox, RN Lacor, J Pitt, WL Klein, Cell Mol Neurobiol 2011 31 939 948 10.1007/s10571-011-9691-4 21538118
19. Globular and protofibrillar Aβ aggregates impair neurotransmission by different mechanism. J Moreth, KS Kroker, D Schwanzar, C Schnack, CAF von Arnim, B Hengerer, H Rosenbrock, L Kussmaul, Biochem 2013 52 1466 1476 10.1021/bi3016444
20. Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediated. DM Walsh, A Lamakin, GB Benedek, MM Condron, DB Teplow, J Biol Chem 1997 272 22364 22372 10.1074/jbc.272.35.22364 9268388 (Pubitemid 27382873)
21. An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments. Y Fezoui, DM Hartley, JD Harper, R Khurana, DM Walsh, MM Condron, DJ Selkoe, PT Lansbury, AL Finnk, DB Teplow, Amyloid 2000 7 166 178 10.3109/13506120009146831 11019857
22. Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. S Lee, EJ Fernandez, TA Good, Protein Sci 2007 16 723 732 10.1110/ps.062514807 17327396 (Pubitemid 46507001)
23. Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. AK Paravastu, I Qahwash, RD Leapman, SC Meredith, R Tycko, Proc Natl Acad Sci USA 2009 106 7443 7448 10.1073/pnas.0812033106 19376973
24. Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Aβ peptide by CD, TEM, STEM and in situ AFM. N Norlin, M Hellberg, A Filippov, AA Sousa, G Gröbner, RD Leapman, N Almqvist, ON Antzutkin, J Struct Biol 2012 180 174 189 10.1016/j.jsb.2012.06.010 22750418
25. Assembly of Alzheimer's Aβ peptide into nanostructured amyloid fibrils. I Morgado, M Fändrich, Curr Opin Colloid Interface Sci 2011 16 508 514 10.1016/j.cocis.2011.06.016
26. Toxicity of pyroglutaminated amyloid β-peptides 3(pE)-40 and -42 is similar to that of Aβ1-40 and -42. TL Tekirian, AY Yang, C Glabe, JW Geddes, J Neurochem 1999 73 1584 1589 10501204 (Pubitemid 29440160)
27. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. AE Roher, JD Lowenson, S Clarke, AS Woods, RJ Cotter, E Gowing, ML Ball, Proc Natl Acad Sci USA 1993 90 10836 10840 10.1073/pnas.90.22.10836 8248178 (Pubitemid 23347138)
28. The development of amyloid beta protein deposits in the aged brain. DR Thal, E Capetillo-Zarate, K Del Tredici, H Braak, Sci Aging Knowledge Environ 2006 2006 e1 16525193
29. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. MB Podlisny, BL Ostaszewski, SL Squazzo, EH Koo, RE Rydell, DB Teplow, DJ Selkoe, J Biol Chem 1995 270 9564 9570 10.1074/jbc.270.16.9564 7721886
30. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. DM Walsh, I Klyubin, JV Fadeeva, MJ Rowan, DJ Selkoe, Biochem Soc Trans 2002 30 552 557 12196135 (Pubitemid 35001597)
31. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. JP Cleary, DM Walsh, JJ Hofmeister, GM Shankar, MA Kushowski, DJ Selkoe, KH Ashe, Nat Neurosci 2005 8 79 84 10.1038/nn1372 15608634 (Pubitemid 41236735)
32. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers. M Townsend, JP Cleary, T Mehta, J Hofmeister, S Lesne, E O'Hare, DM Walsh, DJ Selkoe, Ann Neurol 2006 60 668 676 10.1002/ana.21051 17192927 (Pubitemid 46048484)
33. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. MN Reed, JJ Hofmeister, L Jungbauer, AT Welzel, C Yu, MA Sherman, S Lesné MJ LaDu, DM Walsh, KH Ashe, JP Cleary, Neurobiol Aging 2011 32 1784 1794 10.1016/j.neurobiolaging.2009.11.007 20031278
34. Aβ oligomers inhibit synapse remodeling necessary for memory consolidation. DB Freir, R Fedriani, D Scully, IM Smith, DJ Selkoe, DM Walsh, CM Regan, Neurobiol Aging 2011 32 2211 2218 10.1016/j.neurobiolaging.2010.01.001 20097446
35. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. GM Shankar, S Li, TH Mehta, A Garcia-Munoz, NE Shepardson, I Smith, FM Brett, MA Farrell, MJ Rowan, CA Lemere, CM Regan, DM Walsh, BL Sabatini, DJ Selkoe, Nat Med 2008 14 837 842 10.1038/nm1782 18568035
36. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. M Townsend, GM Shankar, T Mehta, DM Walsh, DJ Selkoe, J Physiol 2006 572 477 492 10.1113/jphysiol.2005.103754 16469784
37. A specific amyloid-β protein assembly in the brain impairs memory. S Lesné MT Koh, L Kotilinek, R Kayed, CG Glabe, A Yang, M Gallagher, KH Ashe, Nature 2006 440 352 357 10.1038/nature04533 16541076
38. Distinct early folding and aggregation properties of Alzheimer amyloid-β peptides Aβ40 and Aβ42. Y-R Chen, CG Clabe, J Biol Chem 2006 281 24414 24422 10.1074/jbc.M602363200 16809342 (Pubitemid 44274214)
39. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. G Bitan, SS Vollers, DB Teplow, J Biol Chem 2003 278 34882 34889 10.1074/jbc.M300825200 12840029 (Pubitemid 37102247)
40. 1-42 oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. S Barghorn, V Nimmrich, A Striebinger, C Krantz, P Keller, B Janson, M Bahr, M Schmidt, RS Bitner, J Harlan, E Barlow, U Ebert, H Hillen, J Neurochem 2005 95 834 847 10.1111/j.1471-4159.2005.03407.x 16135089 (Pubitemid 41567174)
41. Soluble Aβ oligomer production and toxicity. ME Larson, SE Lesné J Neurochem 2012 120 Suppl 1 125 139 22121920
42. Diffusible, non-fibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. MP Lambert, AK Barlow, BA Chromy, C Edwards, R Freed, M Liosatos, TE Morgan, I Rozovsky, B Trommer, KL Viola, P Wals, C Zhang, CE Finch, GA Krafft, WL Klein, Proc Natl Acad Sci USA 1998 95 6448 6453 10.1073/pnas.95.11.6448 9600986 (Pubitemid 28249033)
43. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. WB Stine, KN Dahlgren, GA Krafft, MJ LaDu, J Mol Biol 2003 278 11612 11622 (Pubitemid 36792723)
44. Solution state characterization of amyloid β-derived diffusible ligands. RW Hepler, KM Grimm, DD Nahas, R Breese, EC Dodson, P Acton, PM Keller, M Yeager, H Wang, P Shughrue, G Kinney, JG Joyce, Biochem 2006 45 15157 15167 10.1021/bi061850f (Pubitemid 46032442)
45. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. A Deshpande, E Mina, C Glabe, J Busciglio, J Neurosci 2006 26 6011 6018 10.1523/JNEUROSCI.1189-06.2006 16738244 (Pubitemid 44318367)
46. Fibril specific, conformation depended antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. R Kayed, E Head, F Sarsoza, T Saing, CW Cotman, M Necula, L Margol, J Wu, L Breydo, JL Thompson, S Rasool, T Gurlo, P Butler, CG Glabe, Mol Neurodegen 2007 2 18 10.1186/1750-1326-2-18 (Pubitemid 350209643)
47. Amyloid-β(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. V Rangachari, BD Moore, DK Reed, LK Sonoda, AW Bridges, E Conboy, D Hartigan, TL Rosenberry, Biochem 2007 46 12451 12462 10.1021/bi701213s (Pubitemid 350027406)
48. Aβ-globulomers are formed independently of the fibril pathway. GP Gellermann, H Byrnes, A Striebinger, K Ullrich, R Mueller, H Hillen, S Barghorn, Neurobiol Dis 2008 30 212 220 10.1016/j.nbd.2008.01.010 18353662
49. Amyloid β oligomers (Aβ1-42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. V Nimmrich, C Grimm, A Draguhn, S Barghorn, A Lehmann, H Schoemaker, H Hillen, G Gross, U Ebert, C Bruehl, J Neurosci 2008 28 788 797 10.1523/JNEUROSCI.4771-07.2008 18216187 (Pubitemid 351159014)
50. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. A Demuro, E Mina, R Kayed, SC Milton, I Parker, CG Glabe, J Biol Chem 2005 280 17294 17300 10.1074/jbc.M500997200 15722360 (Pubitemid 41389198)
51. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β M Hoshi, M Sato, S Matsumoto, A Noguchi, K Yasutake, N Yoshida, K Sato, Proc Natl Acad Sci USA 2003 100 6370 6575 10.1073/pnas.1237107100 12750461 (Pubitemid 36666588)
52. Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. A Noguchi, S Matsumura, M Dezawa, M Tada, M Yanazawa, A Ito, M Akioka, S Kikuchi, M Sato, S Ideno, M Noda, A Fukunari, S-i Muramatsu, Y Itokazu, K Sato, H Takahashi, DB Teplow, Y-i Nabeshima, A Kakita, K Imahori, M Hoshi, J Biol Chem 2009 284 32895 32905 10.1074/jbc.M109.000208 19759000
53. Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. DM Walsh, DM Hartley, Y Kusumoto, Y Fezoui, MM Condron, AL Lomakin, GB Benedek, DJ Selkoe, DB Teplow, J Biol Chem 1999 274 25945 25952 10.1074/jbc.274.36.25945 10464339 (Pubitemid 29418632)
54. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. JD Harper, SS Wong, CM Lieber, PT Lansbury Jr, Biochem 1999 38 8972 8980 10.1021/bi9904149 (Pubitemid 29334658)
55. Mixtures of wild-type and a pathogenic (E22G) form of Aβ40 in vitro accumulate protofibrils, including amyloid pores. HA Lashuel, DM Hartley, BM Petre, JS Wall, MN Simon, T Walz, PT Lansbury, J Mol Biol 2003 332 795 808 10.1016/S0022-2836(03)00927-6 12972252 (Pubitemid 37101368)
56. Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. CA Lasagna-Reeves, CG Glabe, R Kayed, J Biol Chem 2011 286 22122 22130 10.1074/jbc.M111.236257 21507938
57. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. PD Mehta, T Pirttilä SP Mehta, EA Sersen, PS Aisen, HM Wisniewski, Arch Neurol 2000 57 100 105 10.1001/archneur.57.1.100 10634455 (Pubitemid 30027637)
58. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. A Delacourte, N Sergeant, D Champain, A Wattez, C-A Maurage, F Lebert, F Pasquier, J-P David, Neurology 2002 59 398 407 10.1212/WNL.59.3.398 12177374 (Pubitemid 34857933)
59. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. H Fukumoto, T Tokuda, T Kasai, N Ishigami, H Hidaka, M Kondo, D Allsop, M Nakagawa, FASEB J 2010 24 2716 2726 10.1096/fj.09-150359 20339023
60. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. E Karran, M Mercken, B De Stropper, Nat Rev Drug Disc 2011 10 698 712 10.1038/nrd3505
61. A quantitative assay selective for amyloid oligomer species differentiates cerebrospinal fluid from Alzheimer's disease and age-matched normal. A Wolfe, A McCampbell, N Hatcher, K Tugusheva, S Haugabook, J Maxwell, G Wu, B Howell, J Renger, P Shughrue, M Savage, Alzheimers Dementia 2012 8 Supplement 278
62. Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. M Hölttä O Hansson, U Andreasson, J Hertze, L Minthon, K Nägga, N Andreasen, H Zetterberg, K Blennow, PLoS One 2013 8 66381 10.1371/journal.pone.0066381 23799095
63. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. L-F Lue, Y-M Kuo, AE Roher, L Brachova, Y Shen, L Sue, T Beach, JH Kurth, RE Rydel, J Rogers, Am J Pathol 1999 155 853 862 10.1016/S0002-9440(10)65184-X 10487842 (Pubitemid 29426831)
64. The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain. JM McDonald, NJ Cairns, L Taylor-Reinwald, D Holtzman, DM Walsh, Brain Res 2012 1450 138 147 22440675
65. A sensitive Aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. MJ Savage, J Kalinina, A Wolfe, K Tugusheva, R Korn, T Cash-Mason, JW Maxwell, NG Hatcher, SJ Haugabook, G Wu, BJ Howell, JJ Renger, PJ Shughrue, A McCampbell, J Neurosci 2014 34 2884 2897 10.1523/JNEUROSCI.1675-13.2014 24553930
66. Direct observation of single amyloid-β(1-40) oligomers on live cells: binding and growth at physiological concentrations. RD Johnson, JA Schauerte, KC Wisser, A Gafni, DG Steel, PLoS One 2011 6 23970 10.1371/journal.pone.0023970 21901146
67. Single-molecule imaging reveals Aβ42:Aβ40 ratio-dependent oligomer growth on neuronal processes. RD Johnson, JA Schauerte, C-C Chang, KC Wisser, JC Althaus, CJL Carruthers, MA Sutton, DG Steel, A Gafni, Biophys J 2013 104 894 903 10.1016/j.bpj.2012.12.051 23442968
68. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. PT Lansbury, Proc Natl Acad Sci USA 1999 96 3342 3344 10.1073/pnas.96.7.3342 10097040 (Pubitemid 29168913)
69. Alzheimer's amyloid fibrils: structure and assembly. LC Serpell, Biochim Biophys Acta 2000 1502 16 30 10.1016/S0925-4439(00)00029-6 10899428 (Pubitemid 30433852)
70. In-situ atomic force microscopy study of β-amyloid fibrillization. HK Blackley, GH Sanders, MC Davies, CJ Roberts, SJ Tendler, MJ Wilkinson, J Mol Biol 2000 298 833 840 10.1006/jmbi.2000.3711 10801352
71. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. MD Kirkitadze, MM Condron, DB Teplow, J Mol Biol 2001 312 1103 1119 10.1006/jmbi.2001.4970 11580253 (Pubitemid 32980329)
72. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. B Caughey, PT Lansbury, Annu Rev Neurosci 2003 26 267 298 10.1146/annurev.neuro.26.010302. 081142 12704221 (Pubitemid 37064935)
73. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. SI Cohen, S Linse, LM Luheshi, E Hellstrand, DA White, L Rajah, DE Otzen, M Vendruscolo, CM Dobson, TP Knowles, Proc Natl Acad Sci USA 2013 110 9758 9763 10.1073/pnas.1218402110 23703910
74. Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation. JS Jeong, A Ansaloni, R Mezzenga, HA Lashuel, G Dietler, J Mol Biol 2013 425 1765 1781 10.1016/j.jmb.2013.02.005 23415897
75. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. M Stefani, FEBS J 2010 277 4602 4613 10.1111/j.1742-4658.2010.07889.x 20977664
76. The γ -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]- S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. TA Lanz, CS Himes, G Pallante, L Adams, S Yamazaki, B Amore, KM Merchant, J Pharmacol Exp Ther 2003 305 864 871 10.1124/jpet.102.048280 12626636 (Pubitemid 36617962)
77. Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. DM Barten, VL Guss, JA Corsa, A Loo, SB Hansel, M Zheng, B Munoz, K Srinivasan, B Wang, BJ Robertson, CT Polson, J Wang, SB Roberts, JP Hendrick, JJ Anderson, JK Loy, R Denton, TA Verdoorn, DW Smith, KM Felsenstein, J Pharmacol Exp Ther 2005 312 635 643 15452193 (Pubitemid 40189561)
78. Dynamics of Aβ turnover and deposition in different β-amyloid precursor protein transgenic mouse models following γ-secretase inhibition. D Abramowski, K-H Wiederhold, U Furrer, A-L Jaton, A Neuenschwander, M-J Runser, S Danner, J Reichwald, D Ammaturo, D Staab, M Stoeckli, H Rueeger, U Neumann, M Staufenbiel, J Pharmacol Exp Ther 2008 327 411 424 10.1124/jpet.108.140327 18687920
79. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. M Garcia-Alloza, M Subramanian, D Thyssen, LA Borrelli, A Fauq, P Das, TE Golde, BT Hyman, BJ Bacskai, Mol Neurodegen 2009 4 19 10.1186/1750-1326-4-19
80. Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease. JL Jankowsky, HH Slunt, V Gonzales, AV Savonenko, JC Wen, NA Jenkins, NG Copeland, LH Younkin, HA Lester, SG Younkin, DR Borchelt, PLoS Med 2005 2 355 10.1371/journal.pmed.0020355 16279840 (Pubitemid 43020991)
81. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. T Melnikova, S Fromholt, HS Kim, D Lee, G Xu, A Price, BD Moore, TE Golde, KM Felsenstein, A Savonenko, DR Borchelt, J Neurosci 2013 33 3765 3779 10.1523/JNEUROSCI.4251-12.2013 23447589
82. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. P Das, MP Murphy, LA Younkin, SG Younkin, TE Golde, Neurobiol Aging 2001 22 721 727 10.1016/S0197-4580(01)00245-7 11705631 (Pubitemid 33055611)
83. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. IH Cheng, K Scearce-Levie, J Legleiter, JJ Palop, H Gerstein, N Bien-Ly, J Puoliväli, S Lesné KH Ashe, PJ Muchowski, L Mucke, J Biol Chem 2007 282 23818 23828 10.1074/jbc.M701078200 17548355 (Pubitemid 47328006)
84. Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function. S Lesné L Kotilinek, KH Ashe, Neurosci 2008 151 745 749 10.1016/j.neuroscience.2007.10.054
85. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. JR Cirrito, PC May, MA O'Dell, JW Taylor, M Parsadanian, JW Cramer, JE Audia, JS Nissen, KR Bales, SM Paul, RB DeMattos, DM Holtzman, J Neurosci 2003 23 8844 8853 14523085 (Pubitemid 37210896)
86. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF vs. parenchymal Aβ during age-related plaque formation. S Hong, O Quintero-Monzon, BL Ostaszewski, DR Podlisny, WT Cavanaugh, T Yang, DM Holtzman, JR Cirrito, DJ Selkoe, J Neurosci 2011 31 15861 15869 10.1523/JNEUROSCI.3272-11.2011 22049429
87. Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. S Takeda, T Hashimoto, AD Roe, Y Hori, TL Spires-Jones, BT Hyman, FASEB J 2013 27 3239 3248 10.1096/fj.13-229666 23640054
88. Single molecule characterization of the interactions between amyloid-β peptides and the membranes of hippocampal cells. P Narayan, KA Ganzinger, J McColl, L Weimann, S Meehan, S Qamar, JA Carver, MR Wilson, P St George-Hyslop, CM Dobson, D Klenerman, J Am Chem Soc 2013 135 1491 1498 10.1021/ja3103567 23339742
89. Amyloid β protein (Aβ) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). SA Gravina, L Ho, CB Eckman, KE Long, L Otvos, LH Younkin, N Suzuki, SG Younkin, J Biol Chem 1995 270 7013 1016 10.1074/jbc.270.13.7013 7706234
90. Kinetics and thermodynamics of amyloid fibril assembly. R Wetzel, Acc Chem Res 2006 39 671 679 10.1021/ar050069h 16981684
91. Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties. L Sánchez, S Madurga, T Pukala, M Vilaseca, C López-Iglesias, CV Robinson, E Giralt, N Carulla, J Am Chem Soc 2011 133 6505 6508 10.1021/ja1117123 21486030
92. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. WP Esler, ER Stimson, JM Jennings, HV Vinters, JR Ghilardi, JP Lee, PW Mantyh, JE Maggio, Biochem 2000 39 6288 6295 10.1021/bi992933h (Pubitemid 30347132)
93. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. RM Koffie, M Mayer-Luehmann, T Hashimoto, KW Adams, ML Mielke, M Garcia-Alloza, KD Micheva, SJ Smith, ML Kim, VM Lee, BT Hyman, TL Spires-Jones, Proc Natl Acad Sci USA 2009 106 4012 4017 10.1073/pnas.0811698106 19228947
94. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β CA Atwood, ME Obrenovich, T Liu, H Chan, G Perry, MA Smith, RN Martins, Brain Res Rev 2003 43 1 16 10.1016/S0165-0173(03)00174-7 14499458 (Pubitemid 37130077)
95. β-Amyloid monomers are neuroprotective. ML Giuffrida, F Caraci, B Pagnataro, S Cataldo, P De Bona, V Bruno, G Molinaro, G Pappalardo, A Messina, A Palmigiano, D Garozzo, F Nicoletti, E Rizzarelli, A Copani, J Neurosci 2009 29 10582 10587 10.1523/JNEUROSCI.1736-09.2009 19710311
96. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. S Baglioni, F Casamenti, M Bucciantini, LM Luheshi, N Taddei, F Chiti, CM Dobson, M Stefani, J Neurosci 2006 26 8160 8162 10.1523/JNEUROSCI. 4809-05.2006 16885229 (Pubitemid 44315140)
97. Amyloid deposits: protection against toxic protein species? S Treusch, DM Cyr, S Lindquist, Cell Cycle 2009 8 1668 1674 10.4161/cc.8.11.8503 19411847
98. Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. T Oda, P Wals, HH Osterburg, SA Johnson, GM Pasinetti, TE Morgan, I Rozovsky, WB Stine, SW Snyder, TF Holzman, GA Krafft, CE Finch, Exp Neurobiol 1995 136 22 31 10.1006/exnr.1995.1080
99. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. JB Standridge, Curr Alzheimers Res 2006 3 95 107 10.2174/ 156720506776383068
100. 2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. H Zemple, E Thies, E Mandelkow, EM Mandelkow, J Neurosci 2010 30 11938 11950 10.1523/JNEUROSCI.2357-10.2010 20826658
101. Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. I Klyubin, WK Cullen, N-W Hu, MJ Rowan, Molecular Brain 2012 5 25 10.1186/1756-6606-5-25 22805374
102. Natural amyloid-beta oligomers acutely impair the formation of a contextual fear memory in mice. KA Kittelberger, F Piazza, G Tesco, LG Reijmers, PLoS One 2012 7 29940 10.1371/journal.pone.0029940 22238679
103. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. D Puzzo, L Privitera, E Leznik, M Fà A Staniszewski, A Palmeri, O Arancio, J Neurosci 2008 28 14537 14545 10.1523/JNEUROSCI.2692-08.2008 19118188
104. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. D Puzzo, L Privitera, M Fà A Staniszewski, G Hashimoto, F Aziz, M Sakurai, EM Ribe, CM Troy, M Merchen, SS Jung, A Palmeri, O Arancio, Ann Neurol 2011 69 819 830 10.1002/ana.22313 21472769
105. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? D Puzzo, O Arancio, J Alzheimers Dis 2013 33 111 S120 22735675
106. Synaptic targeting by Alzheimer's-related amyloid β oligomers. PN Lacor, MC Buniel, L Chang, SJ Fernandez, Y Gong, KL Viola, MP Lambert, PT Velasco, EH Bigio, CE Finch, GA Krafft, WL Klein, J Neurosci 2004 24 10191 10200 10.1523/JNEUROSCI.3432-04.2004 15537891 (Pubitemid 39492046)
107. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. PN Lacor, MC Buniel, PW Furlow, AS Clemente, PT Velasco, M Wood, KL Viola, WL Klein, J Neurosci 2007 27 796 807 10.1523/JNEUROSCI.3501-06.2007 17251419 (Pubitemid 46174498)
108. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. PJ Shughrue, PJ Acton, RS Breese, W-Q Zhao, E Chen-Dodson, RW Hepler, AL Wolfe, M Matthews, GJ Heidecker, JG Joyce, SA Villarreal, JJ Kinney, Neurobiol Aging 2010 31 189 202 10.1016/j.neurobiolaging.2008.04.003 18486276
109. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. G Rammes, A Hasenjager, K Sroka-Saidi, JM Deussing, CG Parsons, Neuropharmacology 2011 60 982 990 10.1016/j.neuropharm.2011.01.051 21310164
110. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. A Poling, K Paisley-Morgan, JJ Panos, E-M Kim, E O'Hare, JP Cleary, S Lesné KH Ashe, M Porritt, L Baker, Behav Brain Res 2008 193 230 234 10.1016/j.bbr.2008.06.001 18585407
111. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. FG De Felice, D Wu, MP Lambert, SJ Fernandez, PT Velasco, PN Lacor, EH Bigio, J Jerecic, PJ Acton, PJ Shughrue, E Chen-Dodson, GG Kinney, WL Klein, Neurobiol Aging 2008 29 1334 1347 10.1016/j.neurobiolaging.2007.02.029 17403556 (Pubitemid 351970596)
112. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. M Jin, N Shepardson, T Yang, G Chen, D Walsh, DJ Selkoe, Proc Natl Acad Sci USA 2011 108 5819 5824 10.1073/pnas.1017033108 21421841
113. Soluble Aβ promotes wild-type tau pathology in vivo. MA Chabrier, M Blurton-Jones, AA Agazaryan, JL Nerhus, H Martinez-Coria, FM LaFerla, J Neurosci 2012 32 17345 17350 10.1523/JNEUROSCI.0172-12.2012 23197725
114. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease: a link between Aβ and tau pathology. S Oddo, A Caccamo, L Tran, MP Lambert, CG Glabe, WL Klein, FM LaFerla, J Biol Chem 2006 281 1599 1604 10.1074/jbc.M507892200 16282321
115. Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. SA Small, K Duff, Neuron 2008 60 534 542 10.1016/j.neuron.2008.11. 007 19038212
116. Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. H Zempel, J Luedtke, Y Kumar, J Biernat, H Dawson, E Mandelkow, E-M Kandelkow, EMBO J 2013 32 2920 2937 10.1038/emboj.2013.207 24065130
117. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer's disease brains. YM Kuo, MR Emmerling, C Vigo-Pelfrey, TC Kasunic, JB Kirkpatrick, GH Murdoch, MJ Ball, AE Roher, J Biol Chem 1996 271 4077 4081 10.1074/jbc.271.8.4077 8626743
118. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Y Gong, L Chang, KL Viola, PN Lacor, MP Lambert, CE Finch, GA Krafft, WL Klein, Proc Natl Acad Sci USA 2003 100 10417 10422 10.1073/pnas.1834302100 12925731 (Pubitemid 37071893)
119. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. D Sehlin, H Englund, B Simu, M Karlsson, M Ingelsson, F Nikolajeff, L Lannfelt, FE Pettersson, PLoS One 2012 7 32014 10.1371/journal.pone.0032014 22355408
120. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. DG Georganopoulou, L Chang, J-M Nam, SC Thaxton, EJ Mufson, WL Klein, CA Mirkin, Proc Natl Acad Sci USA 2005 102 2273 2276 10.1073/pnas.0409336102 15695586 (Pubitemid 40279365)
121. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. CM Gao, AY Yam, X Wang, E Magdangal, C Salisbury, D Peretz, RN Zuckermann, MD Connolly, O Hansson, L Minthon, H Zetterberg, K Blennow, JP Fedynyshyn, S Allauzen, PLoS One 2010 5 15725 10.1371/journal.pone. 0015725 21209907
122. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. AN Santos, M Ewers, L Minthon, A Simm, R-E Silber, K Blennow, D Prvulovic, O Hansson, H Hampel, J Alzheimer's Dis 2012 29 171 176 24943344
123. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. TJ Esparza, H Zhao, JR Cirrito, NJ Cairns, RJ Bateman, DM Holtzman, DL Brody, Ann Neurol 2013 73 104 119 10.1002/ana.23748 23225543
124. A luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. AZ Herskovits, JJ Locascio, ER Peskind, G Li, BT Hyman, PLoS One 2013 8 67898 10.1371/journal.pone.0067898 23844122
125. Structural classification of toxic amyloid oligomers. CG Glabe, J Biol Chem 2008 283 29639 29643 10.1074/jbc.R800016200 18723507
126. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. F Rahimi, A Shanmugam, G Bitan, Curr Alzheimer Res 2008 5 319 341 10.2174/156720508784533358 18537546 (Pubitemid 351840280)
127. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. M Fändrich, J Mol Biol 2012 421 427 440 10.1016/j.jmb.2012.01.006 22248587
128. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. AE Roher, MO Chaney, Y-M Kuo, SD Webster, WB Stine, LJ Haverkamp, AS Woods, RJ Cotter, JM Tuohy, GA Krafft, BS Bonnell, MR Emmerling, J Biol Chem 1996 271 20631 20635 10.1074/jbc.271.34. 20631 8702810 (Pubitemid 26281842)
129. Soluble amyloid-β peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. N-W Hu, IM Smith, DM Walsh, MJ Rowan, Brain 2008 131 2414 2424 10.1093/brain/awn174 18678563
130. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. DM Hartley, DM Walsh, CP Ye, T Diehl, S Vasquez, PM Vassilev, DB Teplow, DJ Selkoe, J Neurosci 1999 19 8876 8884 10516307 (Pubitemid 30226709)
131. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. S Peng, DJ Garzon, M Marchese, W Klein, SD Ginsberg, BM Francis, HT Mount, EJ Mufson, A Salehi, M Fahnestock, J Neurosci 2009 29 9321 9329 10.1523/JNEUROSCI.4736-08. 2009 19625522
132. Self-assembly of Aβ1-42 into globular neurotoxins. BA Chromy, RJ Nowak, MP Lambert, KL Viola, L Chang, PT Velasco, BW Jones, SJ Fernandez, PN Lacor, P Horowitz, CE Finch, GA Krafft, WL Klein, Biochem 2003 42 12749 12760 10.1021/bi030029q (Pubitemid 37385806)
133. Structure-neurotoxicity relationships of amyloid β-protein oligomers. K Ono, MM Condron, DB Teplow, Proc Natl Acad Sci USA 2009 106 14745 14750 10.1073/pnas.0905127106 19706468
134. Aβ mediated diminution of MMT reduction-an artefact of single cell culture? R Rönicke, A Klemm, J Meinhardt, UH Schröder, M Fändrich, KG Reymann, PLoS One 2008 3 3236 10.1371/journal.pone.0003236 18800168
135. Oligomerization of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. MB Podlisny, DM Walsh, P Amarante, BL Ostaszewski, ER Stimson, JE Maggio, DB Teplow, DJ Selkoe, Biochemistry 1998 37 3602 3611 10.1021/bi972029u 9521679 (Pubitemid 28162915)
136. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. DM Walsh, I Klyubin, JV Fadeeva, WK Cullen, R Anwyl, MS Wolfe, MJ Rowan, DJ Selkoe, Nature 2002 416 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
137. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. DM Walsh, M Townsend, MB Podlisny, GM Shankar, JV Fadeeva, OE Agnaf, DM Hartley, DJ Selkoe, J Neurosci 2005 25 2455 2462 10.1523/JNEUROSCI.4391-04.2005 15758153 (Pubitemid 40365155)
138. Neurotoxic protein oligomers-what you see is not always what you get. G Bitan, EA Fradinger, SM Spring, DB Teplow, Amyloid 2005 12 88 95 10.1080/13506120500106958 16011984 (Pubitemid 40978716)
139. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. R Kimura, D MacTavish, J Yang, D Westaway, JH Jhamandas, J Neurosci 2012 32 17401 17406 10.1523/JNEUROSCI.3028-12.2012 23197731
140. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. GM Shankar, BL Bloodgood, M Townsend, DM Walsh, DJ Selkoe, BL Sabatini, J Neurosci 2007 27 2866 2875 10.1523/JNEUROSCI.4970-06.2007 17360908 (Pubitemid 46438992)
141. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. S Li, S Hong, NE Shepardson, DM Walsh, GM Shankar, D Selkoe, Neuron 2009 62 788 801 10.1016/j.neuron.2009.05.012 19555648
142. Amyloid beta from axons and dendrites reduces local spine number and plasticity. W Wei, LN Nguyen, HW Kessels, H Hagiwara, S Sisodia, R Malinow, Nat Neurosci 2010 13 190 196 10.1038/nn.2476 20037574
143. NMDA-receptor activation but not ion flux is required for amyloid-beta induced synaptic depression. A Tamburri, A Dudilot, S Licea, C Bourgeois, J Boehm, PLoS One 2013 8 65350 10.1371/journal.pone.0065350 23750255
144. New developments on the role of NMDA receptors in Alzheimer's disease. R Malinow, Curr Opin Neurobiol 2012 22 559 563 10.1016/j.conb.2011.09.001 21962484
145. Sortilin is required for toxic action of Aβ oligomers (AβOs): extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. A Takamura, Y Sato, D Watabe, Y Okamoto, T Nakata, T Kawarabayashi, S Oddo, FM Laferla, M Shoji, E Matsubara, Life Sci 2012 91 1177 1186 10.1016/j.lfs.2012.04.038 22579764
146. 1-42 through p53 and Bax in cultured primary human neurons. Y Zhang, R McLaughlin, C Goodyer, A LeBlanc, J Cell Biol 2002 156 519 529 10.1083/jcb.200110119 11815632 (Pubitemid 34839899)
147. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. OV Vitolo, A Sant'Angelo, V Costanzo, F Battaglia, O Arancio, M Shelanski, Proc Natl Acad Sci USA 2002 99 13217 13221 10.1073/pnas.172504199 12244210
148. Reversal of long-term dendritic spine alterations in Alzheimer disease models. DL Smith, J Pozueta, B Gong, O Arancio, M Shelanski, Proc Natl Acad Sci USA 2009 106 16877 16882 10.1073/pnas.0908706106 19805389
149. Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Q Wang, DM Walsh, MJ Rowan, DJ Selkoe, R Anwyl, J Neurosci 2004 24 3370 3378 10.1523/JNEUROSCI.1633-03.2004 15056716 (Pubitemid 38451902)
150. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. IF Tsigelny, L Crews, P Desplats, GM Shaked, Y Sharikov, H Mizuno, B Spencer, E Rockenstein, M Trejo, O Platoshyn, JX-J Yuan, E Masliah, PLoS One 2008 3 3135 10.1371/journal.pone.0003135 18769546
151. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. M Cisse, B Halabisky, J Harris, N Devidze, DB Dubal, B Sun, A Orr, G Lotz, DH Kim, P Hamto, K Ho, G-Q Yu, L Mucke, Nature 2011 469 47 52 10.1038/nature09635 21113149
152. Endocytic pathways mediating oligomeric Aβ42 neurotoxicity. C Yu, E Nwabuisi-Heath, K Laxton, MJ LaDu, Mol Neurodegener 2010 5 19 10.1186/1750-1326-5-19 20478062
153. Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. M Renner, PN Lacor, PT Velasco, J Xu, A Contractor, WL Klein, A Triller, Neuron 2010 66 739 754 10.1016/j.neuron.2010. 04.029 20547131
154. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. JW Um, AC Kaufman, M Kostylev, JK Heiss, M Stagi, H Takahashi, ME Kerrisk, A Vortmeyer, T Wisniewski, AJ Koleske, EC Gunther, HB Nygaard, SM Strittmatter, Neuron 2013 79 887 902 10.1016/j.neuron.2013.06.036 24012003
155. Isolated amyloid(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. GS Paranjape, LK Gouwens, DC Osborn, MR Nishols, ACS Chem Neurosci 2012 3 302 311 10.1021/cn2001238 22860196
156. The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicity. VG Ostapchenko, FH Beraldo, AH Mohammad, Y-F Xie, PHF Hirata, AC Magalhaes, G Lamour, H Li, A Maciejewski, JC Belrose, BL Teixeira, M Fahnestock, ST Ferreira, NR Cashman, GNM Hajj, MF Jackson, W-Y Choy, JF MacDonald, VR Martins, VF Prado, MAM Prado, J Neurosci 2013 33 16552 16564 10.1523/JNEUROSCI.3214-13.2013 24133259
157. The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers. ND Younan, CJ Sarell, P Davies, DR Brown, JH Viles, FASEB J 2013 27 1847 1858 10.1096/fj.12-222588 23335053
158. Alzheimer amyloid-β oligomer bound to post-synaptic prion protein activates Fyn to impair neurons. JW Um, HB Nygaard, JK Heiss, MA Kostylev, M Stagi, A Vortmeyer, T Wisniewski, EC Gunther, SM Strittmatter, Nat Neurosci 2012 15 1227 1235 10.1038/nn.3178 22820466
159. c-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. M Larson, MA Sherman, F Amar, M Nuvolone, JA Schneider, DA Bennett, A Aguzzi, SE Lesné J Neurosci 2012 32 16857 16871 10.1523/JNEUROSCI.1858-12.2012 23175838
160. Inhibition of calcineurin-mediated endocytosis and α-amino-3- hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptors prevents amyloid β oligomer-induced synaptic disruption. W-Q Zhao, F Santini, R Breese, D Ross, XD Zhang, DJ Stone, M Ferrer, M Townsend, AL Wolfe, MA Seager, GG Kinney, PJ Shughrue, WJ Ray, J Biol Chem 2010 285 7619 7632 10.1074/jbc.M109.057182 20032460
161. Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. H-Y Wu, E Hudry, T Hashimoto, K Kuchibhotla, A Rozkalne, Z Fan, T Spires-Jones, H Xie, M Arbel-Ornath, CL Grosskreutz, BJ Bacskai, BT Hyman, J Neurosci 2010 30 2636 2649 10.1523/JNEUROSCI.4456-09.2010 20164348
162. Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-β revealed by a novel fluorescence resonance energy transfer assay. H-Y Wu, E Hudry, T Hashimoto, K Uemura, Z-Y Fan, O Berezovska, CL Grosskreutz, BJ Bacskai, BT Hyman, J Neurosci 2012 32 5298 5309 10.1523/JNEUROSCI.0227-12.2012 22496575
163. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. T Kim, GS Vidal, M Djurisic, CM William, ME Birnbaum, KC Garcia, BT Hyman, CJ Shatz, Science 2013 341 1399 1404 10.1126/science.1242077 24052308
164. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. M Townsend, T Mehta, DJ Selkoe, J Biol Chem 2007 282 33305 33312 10.1074/jbc.M610390200 17855343 (Pubitemid 350159548)
165. SM Catalano, G Rishton, NJ Izzo, Compositions and methods for treating neurodegenerative disease International Patent Publication Number, WO 2013/029060 A2. 2013
166. Promiscuous Alzheimer's amyloid: yet another partner. I Benilova, B De Strooper, Science 2013 341 1354 1355 10.1126/science.1244166 24052299
167. On the subject of rigor in the study of amyloid β-protein assembly. DB Teblow, Alzheimers Res Ther 2013 5 39 10.1186/alzrt203 23981712
168. Preparing synthetic Aβ in different aggregation states. WB Stine, L Jungbauer, C Yu, MJ LaDu, Methods Mol Biol 2011 670 13 32 20967580
169. An improved method of generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. DA Ryan, WC Narrow, HJ Federoff, WJ Bowers, J Neurosci Methods 2010 190 171 179 10.1016/j.jneumeth. 2010.05.001 20452375
170. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. W Zago, M Buttini, TA Comery, C Nishioka, SJ Gardai, P Seubert, D Games, F Bard, D Schenk, GG Kinney, J Neurosci 2012 32 2696 2702 10.1523/JNEUROSCI.1676-11.2012 22357853
171. Developing therapeutic antibodies for neurodegenerative disease. YJ Yu, RJ Watts, Neurotherapeutics 2013 10 459 472 10.1007/s13311-013-0187-4 23549647
172. Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils. M Ahmed, J Davis, D Aucoin, T Sato, S Ahuja, S Aimoto, JI Elliott, WE Van Nostrand, SO Smith, Nat Struct Mol Biol 2010 17 561 567 10.1038/nsmb.1799 20383142
173. Molecular modeling of the Aβ1-42 peptide from Alzheimer's disease. MO Chaney, SD Webster, YM Kuo, AF Foher, Protein Eng 1998 11 761 767 10.1093/protein/11.9.761 9796824 (Pubitemid 28434485)
174. High-resolution atomic force microscopy of soluble Aβ42 oligomers. IA Mastrangelo, M Ahmed, T Sato, W Liu, C Wang, P Hough, SO Smith, J Mol Biol 2006 358 106 119 10.1016/j.jmb.2006.01.042 16499926
175. Antiparallel β-sheet: a signature structure of the oligomeric amyloid β-peptide. E Cerf, R Sarroukh, S Tamamizu-Kato, L Breydo, S Derclaye, YF Dufrêne, V Narayanaswami, E Goormaghtigh, J-M Ruysschaert, V Raussens, Biochem J 2009 421 415 423 10.1042/BJ20090379 19435461
176. Generation and therapeutic efficacy of highly oligomer-specific β-amyloid antibodies. H Hillen, S Barghorn, A Striebinger, B Labkovsky, R Müller, V Nimmrich, MW Nolte, C Perez-Cruz, I van der Auwera, F van Leuven, M van Gaalen, AY Bespalov, H Schoemaker, JP Sullivan, U Ebert, J Neurosci 2010 30 10369 10379 10.1523/JNEUROSCI.5721-09.2010 20685980
177. ACU-193: a drug candidate antibody that selectively targets soluble Aβ oligomers. GA Krafft, F Hefti, WF Goure, J Jerecic, KS Iverson, P Walicke, J-C Dodart, Alzheimers Dement 2013 9 326
178. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. S Salloway, R Sperling, S Gilman, NC Fox, K Blennow, M Raskind, M Sabbagh, LS Honig, R Doody, CH van Dyck, R Mulnard, J Barakos, KM Gregg, E Liu, I Lieberburg, D Schenk, R Black, M Gundman, Neurol 2009 73 2061 2070 10.1212/WNL.0b013e3181c67808
179. Bapineuzumab. GA Kerchner, AL Boxer, Expert Opin Biol Ther 2010 10 1121 1130 10.1517/14712598.2010.493872 20497044
180. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 1, double-blind, placebo-controlled, ascending-dose study. JO Rinne, DJ Brooks, MN Rossor, NC Fox, R Bullock, WE Klunk, CA Mathis, K Blennow, J Barakos, AA Okello, S Rodriguez Martinez de Liano, E Liu, M Koller, KM Gregg, D Schenk, R Black, M Grundman, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
181. Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. ER Siemers, S Friedrich, RA Dean, CR Gonzales, MR Farlow, SM Paul, RB DeMattos, Clin Neuropharm 2010 33 67 73 10.1097/WNF. 0b013e3181cb577a
182. Can Alzheimer disease be prevented by amyloid-β immunotherapy? CA Lemere, E Masliah, Nat Rev Neurol 2010 6 108 119 10.1038/nrneurol.2009.219 20140000
183. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. M Farlow, SE Arnold, CH van Dyck, PS Aisen, BJ Snider, AP Porsteinsson, S Friedrich, RA Dean, C Gonzales, G Sethuraman, RB DeMattos, R Mohs, SM Paul, ER Siemers, Alzheimers Dement 2012 8 261 271 10.1016/j.jalz.2011.09.224 22672770
184. Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. K Lobello, JM Ryan, E Liu, G Rippon, R Black, Int J Alzheimers Dis 2012 2012 628070 22292124
185. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. ND Prins, P Scheltens, Alzheimers Res Ther 2013 5 56 10.1186/alzrt220 24216217
186. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, R Raman, X Sun, PS Aisen, E Siemers, H Liu-Seifert, R Mohs, N Engl J Med 2014 370 311 321 10.1056/NEJMoa1312889 24450890
187. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. S Salloway, R Sperling, NC Fox, K Blennow, W Klunk, M Raskind, M Sabbagh, LS Honig, AP Porsteinsson, S Ferris, M Reichert, N Ketter, B Nejadnik, V Guenzler, M Miloslavsky, D Wang, Y Lu, J Lull, IC Tudor, E Liu, M Grundman, E Yuen, R Black, RH Brashear, N Engl J Med 2014 370 322 333 10.1056/NEJMoa1304839 24450891
188. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β MM Racke, LI Boone, DL Hepburn, M Parsadainian, MT Bryan, DK Ness, KS Piroozi, WH Jordan, DD Brown, WP Hoffman, DM Holtzman, KR Bales, BD Gitter, PC May, SM Paul, RB DeMattos, J Neurosci 2005 25 629 636 10.1523/JNEUROSCI.4337-04.2005 15659599
189. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. P Seubert, C Vigo-Pelfrey, F Esch, M Lee, H Dovey, D Davis, S Sinha, M Schlossmacher, J Whaley, C Swindlehurst, R McCormack, R Wolfert, D Selkoe, I Lieberbug, D Schenk, Nature 1992 359 325 327 10.1038/359325a0 1406936
190. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. RB DeMattos, KR Bales, DJ Cummins, J-C Dodart, SM Paul, DM Holtzman, Proc Natl Acad Sci USA 2001 98 8850 8855 10.1073/pnas.151261398 11438712 (Pubitemid 32678116)
191. Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ K Yamada, C Yabuki, P Seubert, D Schenk, Y Hori, S Ohtsuki, T Terasaki, T Hashimoto, T Iwatsubo, J Neurosci 2009 29 11393 11398 10.1523/JNEUROSCI.2021-09. 2009 19741145
192. G Basi, JS Jacobsen, Humanized abeta antibodies for use in improving cognition United States Patent Application Publication Number US 2006/0198851 A1. 2006
193. Characterizing the selectivity of an antibody that targets a rare and unstable conformation of the Aβ peptide in Alzheimer's disease. D Toolan, K Tugusheva, S Haugabook, M Feng, A McCampbell, N Hatcher, W-Q Zhao, C-A Gretzula, T Cash-Mason, P Lemaire, M Savage, P Shughrue, J Ray, J Renger, Unpublished internal research report, Merck & Co 2010 [ http://www. acumenpharm.com/News/Toolan.pdf ]
194. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. F Bard, R Barbour, C Cannon, R Carretto, M Fox, D Games, T Guido, K Hoenow, K Hu, K Johnson-Wood, K Khan, D Kholodenko, C Lee, M Lee, R Motter, M Nguyen, A Reed, D Schenk, P Tang, N Vasquez, P Seubert, T Yednock, Proc Natl Acad Sci USA 2003 100 2023 2028 10.1073/pnas.0436286100 12566568 (Pubitemid 36254567)
195. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. D Schenk, R Barbour, W Dunn, G Gordon, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, Z Liao, I Lieberburg, R Motter, L Mutter, F Soriano, G Shopp, N Vasquez, C Vandevert, S Walker, M Wogulis, T Yednock, D Games, P Seubert, Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
196. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. F Bard, C Cannon, R Barbour, R-L Burke, D Games, H Grajeda, T Guido, K Hu, J Huang, K Kohnson-Wood, K Khan, D Kholodenko, M Lee, I Lieberburg, R Motter, M Nguyen, F Soriano, N Vasquez, K Weiss, B Welch, P Seubert, D Schenk, T Yednock, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
197. G Basi, J Saldanha, T Yednock, Humanized antibodies that recognize beta amyloid peptide World Intellectual Property Organization International Publication Number WO 02/46237 A2. 2002
198. 42 deposition in a transgenic mouse model of Alzheimer disease. K Johnson-Wood, M Lee, R Motter, K Hu, G Gordon, R Barbour, K Khan, M Gordon, H Tan, D Games, I Lieberburg, D Schenk, P Seubert, L McConlogue, Proc Natl Acad Sci USA 1997 94 1550 1555 10.1073/pnas.94.4.1550 9037091 (Pubitemid 27087889)
199. β-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. M Buttini, E Masliah, R Barbour, H Grajeda, R Motter, K Kohnson-Wood, K Kham, P Seubert, S Freedman, D Schenk, D Games, J Neurosci 2005 25 9096 9101 10.1523/JNEUROSCI.1697-05.2005 16207868 (Pubitemid 41500817)
200. Immunotherapy reduces vascular amyloid-β in PDAPP mice. S Schroeter, K Khan, R Barbour, M Doan, M Chen, T Guido, D Gill, G Basi, D Schenk, P Seubert, D Games, J Neurosci 2008 28 6787 6793 10.1523/JNEUROSCI.2377-07.2008 18596154
201. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. F Bard, M Fox, S Friedrich, P Seubert, D Schenk, GG Kinney, T Yednock, Exp Neurology 2012 238 38 43 10.1016/j.expneurol.2012.07.022
202. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. K Blennow, H Zetterberg, JO Rinne, S Salloway, J Wei, R Black, M Grundman, E Liu, Arch Nuerol 2012 69 1002 1010 10.1001/archneurol.2012.90
203. A Pfeifer, M Pihlgren, A Muhs, R Watts, Humanized antibodies to amyloid beta World Intellectual Property Organization International Publication Number WO 2008/156622 A1. 2008
204. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ O Adolfsson, M Pihlgren, N Toni, Y Varisco, AL Buccarello, K Antoniello, S Lohmann, K Piorkowska, V Gafner, JK Atwal, J Maloney, M Chen, A Gogineni, RM Weimer, DL Mortensen, M Friesenhahn, C Ho, R Paul, A Pfeifer, A Muhs, RJ Watts, J Neurosci 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
205. A Rosenthal, J Ponns, W-H Ho, JM Grimm, Antibodies directed against amyloid-beta peptide and methods using same World Intellectual Property Organization International Publication Number WO 2006/036291 A2. 2006
206. Intracranial administration of deglycosyoated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. NC Carty, DM Wilcock, A Rosenthal, J Grimm, J Pons, V Ronan, PE Gottschall, MN Gordon, D Morgan, J Neuroinflammation 2006 3 11 10.1186/1742-2094-3-11 16686956 (Pubitemid 43885294)
207. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for treatment of Alzheimer's disease. SL La Porte, SS Bollini, TA Lanz, YN Abdiche, AS Rusnak, W-H Ho, D Kobayashi, O Harrabi, D Pappas, EW Mina, AJ Milici, TT Kawbe, K Bales, JC Lin, J Pons, J Mol Biol 2012 421 525 536 10.1016/j.jmb.2011.11.047 22197375
208. R Nitsch, C Hock, C Esslinger, M Knobloch, K Tissot, Method of providing disease-specific binding molecules and targets World Intellectual Property Organization International Publication Number WO 2008/081008 A1. 2008
209. Molecular characterization and preclinical efficacy. R Dunstan, T Bussiere, K Rhodes, T Engber, M Maier, P Weinreb, J Grimm, R Nitsch, M Arustu, F Qian, M Li, Alzheimers Dement 2011 7 457
210. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. H Englund, D Sehlin, A-S Johansson, LNG Nilsson, P Gellerfors, S Paulie, L Lannfelt, FE Pettersson, J Neurochem 2007 103 334 345 17623042 (Pubitemid 47404222)
211. The 'Artic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. C Nilsberth, A Westlind-Danielsson, CB Eckman, MM Condron, K Axelman, C Forsell, C Stenh, J Luthman, DB Teplow, SG Younkin, J Näslund, L Lannfelt, Nat Neurosci 2001 4 887 893 10.1038/nn0901-887 11528419 (Pubitemid 32801591)
212. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. R Kayed, E Head, JL Thompson, TM McIntire, SC Milton, CW Cotman, CG Glabe, Science 2003 300 486 489 10.1126/science.1079469 12702875 (Pubitemid 36444329)
213. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. A Lord, A Gumucio, H Englund, D Sehlin, VS Sundquist, L Söderberg, C Möller, P Gellerfors, L Lannfelt, FE Pettersson, LN Nilsson, Neurobiol Dis 2009 36 425 434 10.1016/j.nbd.2009.08.007 19703562
214. P Gellerfors, L Lannfelt, D Sehlin, FE Pettersson, H Englund, Protofibril selective antibodies and the use thereof United States Patent Application Publication Number US 2009/0258009 A1. 2009
215. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β B Bohrmann, K Baumann, J Benz, F Gerber, W Huber, F Knoflach, J Messer, K Oroszlan, R Rauchenberger, WF Richter, C Rothe, M Urban, M Bardroff, M Winter, C Nordstedt, H Loetscher, J Alzheimers Dis 2012 28 49 69 21955818
216. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. S Ostrowitzki, D Deptula, L Thurfjell, F Barkhof, B Bohrmann, DJ Brooks, WE Klunk, E Ashford, K Yoo, Z-X Xu, H Loetscher, L Santarelli, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
217. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease. N Schupf, MX Tang, H Fukuyama, J Manly, H Andrews, P Mehta, J Ravetch, R Mayeux, Proc Natl Acad Sci USA 2008 105 14052 14057 10.1073/pnas.0805902105 18779561
218. J Ravetch, H Fukuyama, Antibodies specific for the protofibril form of beta-amyloid protein World Intellectual Property Organization, International Publication Number WO 2009/065054 A3. 2009
219. SAR228810: an antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). L Pradier, C Cohen, V Blanchard, T Debeir, P Barneoud, T Canton, J Menager, A Bohme, T Rooney, M-C Guillet, B Cameron, Y Shi, S Naimi, J Ravetch, S Claudel, J Alam, Alzheimers Dement 2013 9 808 P809
220. N Baurin, F Blanche, B Cameron, M Duchesne, V Mikol, S Naimi, L Pradier, Y Shi, Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide United States Patent Application Publication No. US 2012/0177639. 2012
221. Naturally occurring autoantibodies against β-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. R Dodel, K Balakrishnan, K Keyvani, O Deuster, F Neff, L-C Andrei-Selmer, S Röskam, C Stüer, Y Al-Abed, C Noelker, M Balzer-Geldsetzer, W Oertel, Y Du, M Bacher, J Neurosci 2011 31 5847 5854 10.1523/JNEUROSCI.4401-10.2011 21490226
222. Autoantibodies to redox-modified oligomeric Aβ are attenuated in the plasma of Alzheimer's disease patients. RD Moir, KA Tseitlin, S Soscia, BT Hyman, MC Irizarry, RE Tanzi, J Biol Chem 2005 280 17458 17463 10.1074/jbc.M414176200 15728175 (Pubitemid 41389217)
223. Natural human antibodies to amyloid beta peptide. P Szabo, N Relkin, ME Weksler, Autoimmunity Rev 2008 7 415 420 10.1016/j.autrev.2008.03.007
224. Monoclonal antibodies that target pathological assemblies of Aβ MP Lambert, PT Velasco, L Chang, KL Viola, S Fernandez, PN Lacor, D Khuon, Y Gong, EH Bigio, P Shaw, FG De Felice, GA Krafft, WL Klein, J Neurochem 2007 100 23 35 10.1111/j.1471-4159.2006.04157.x 17116235 (Pubitemid 46085837)